|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Colombo N, Van Gorp T, Parma G, et al:
Ovarian cancer. Crit Rev Oncol Hematol. 60:159–179. 2006.
View Article : Google Scholar
|
|
3.
|
Moss C and Kaye SB: Ovarian cancer:
progress and continuing controversies in management. Eur J Cancer.
38:1701–1707. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Hockel M and Vaupel P: Tumor hypoxia:
definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Dang CV and Semenza GL: Oncogenic
alterations of metabolism. Trends Biochem Sci. 24:68–72. 1999.
View Article : Google Scholar
|
|
6.
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Cummins EP and Taylor CT:
Hypoxia-responsive transcription factors. Pflugers Arch.
450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Licausi F, Weits DA, Pant BD, Scheible WR,
Geigenberger P and van Dongen JT: Hypoxia responsive gene
expression is mediated by various subsets of transcription factors
and miRNAs that are determined by the actual oxygen availability.
New Phytol. 190:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
10.
|
Christofk HR, Vander Heiden MG, Harris MH,
et al: The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Pouyssegur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Kaelin WG Jr and Ratcliffe PJ: Oxygen
sensing by metazoans: the central role of the HIF hydroxylase
pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Blancher C, Moore JW, Talks KL, Houlbrook
S and Harris AL: Relationship of hypoxia-inducible factor
(HIF)-1alpha and HIF-2alpha expression to vascular endothelial
growth factor induction and hypoxia survival in human breast cancer
cell lines. Cancer Res. 60:7106–7113. 2000.
|
|
15.
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
16.
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Pralhad T, Madhusudan S and Rajendrakumar
K: Concept, mechanisms and therapeutics of angiogenesis in cancer
and other diseases. J Pharm Pharmacol. 55:1045–1053. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Semenza GL: HIF-1 and tumor progression:
pathophysiology and therapeutics. Trends Mol Med. 8:S62–S67. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Chi JT, Wang Z, Nuyten DS, et al: Gene
expression programs in response to hypoxia: cell type specificity
and prognostic significance in human cancers. PLoS Med. 3:e472006.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Imai T, Horiuchi A, Wang C, et al: Hypoxia
attenuates the expression of E-cadherin via up-regulation of SNAIL
in ovarian carcinoma cells. Am J Pathol. 163:1437–1447. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Horiuchi A, Imai T, Shimizu M, et al:
Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and
cell cycle-related molecules in ovarian cancer cells. Anticancer
Res. 22:2697–2702. 2002.PubMed/NCBI
|
|
23.
|
Horiuchi A, Hayashi T, Kikuchi N, et al:
Hypoxia upregulates ovarian cancer invasiveness via the binding of
HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response
element of S100A4 gene. Int J Cancer. 131:1755–1767. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Osada R, Horiuchi A, Kikuchi N, et al:
Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible
factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian
neoplasms and allelic loss of von Hippel-Lindau gene: nuclear
expression of hypoxia-inducible factor 1alpha is an independent
prognostic factor in ovarian carcinoma. Hum Pathol. 38:1310–1320.
2007.
|
|
25.
|
Ambros V: MicroRNA pathways in flies and
worms: growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: Bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Reinhart BJ, Slack FJ, Basson M, et al:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Jay C, Nemunaitis J, Chen P, Fulgham P and
Tong AW: miRNA profiling for diagnosis and prognosis of human
cancer. DNA Cell Biol. 26:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Yu SL, Chen HY, Yang PC and Chen JJ:
Unique microRNA signature and clinical outcome of cancers. DNA Cell
Biology. 26:283–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Qiang R, Wang F, Shi LY, et al: Plexin-B1
is a target of miR-214 in cervical cancer and promotes the growth
and invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Au Yeung CL, Tsang TY, Yau PL and Kwok TT:
Human papillomavirus type 16 E6 induces cervical cancer cell
migration through the p53/microRNA-23b/urokinase-type plasminogen
activator pathway. Oncogene. 30:2401–2410. 2011.
|
|
33.
|
Xu CX, Xu M, Tan L, et al: MicroRNA
miR-214 regulates ovarian cancer cell stemness by targeting
p53/Nanog. J Biol Chem. 287:34970–34978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ye G, Fu G, Cui S, et al: MicroRNA 376c
enhances ovarian cancer cell survival by targeting activin
receptor-like kinase 7: implications for chemoresistance. J Cell
Sci. 124:359–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Vecchione A, Belletti B, Lovat F, et al: A
microRNA signature defines chemoresistance in ovarian cancer
through modulation of angiogenesis. Proc Natl Acad Sci USA.
110:9845–9850. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Mutharasan RK, Nagpal V, Ichikawa Y and
Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes
through Akt- and p53-dependent pathways and exerts cyto-protective
effects. Am J Physiol Heart Circ Physiol. 301:H1519–H1530. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Biswas S, Roy S, Banerjee J, et al:
Hypoxia inducible microRNA 210 attenuates keratinocyte
proliferation and impairs closure in a murine model of ischemic
wounds. Proc Natl Acad Sci USA. 107:6976–6981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Merlo A, de Quiros SB, Secades P, et al:
Identification of a signaling axis HIF-1alpha/microRNA-210/ISCU
independent of SDH mutation that defines a subgroup of head and
neck paragangliomas. J Clin Endocrinol Metab. 97:E2194–E2200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Wang H, Bian S and Yang CS: Green tea
polyphenol EGCG suppresses lung cancer cell growth through
upregulating miR-210 expression caused by stabilizing HIF-1alpha.
Carcinogenesis. 32:1881–1889. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Camps C, Buffa FM, Colella S, et al:
hsa-miR-210 is induced by hypoxia and is an independent prognostic
factor in breast cancer. Clin Cancer Res. 14:1340–1348. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Gou D, Ramchandran R, Peng X, et al:
miR-210 has an anti-apoptotic effect in pulmonary artery smooth
muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol.
303:L682–L691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Fasanaro P, D’Alessandra Y, Di Stefano V,
et al: MicroRNA-210 modulates endothelial cell response to hypoxia
and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol
Chem. 283:15878–15883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
44.
|
Kim SW, Li Z, Moore PS, et al: A sensitive
non-radioactive northern blot method to detect small RNAs. Nucleic
Acids Res. 38:e982010. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Greijer AE and van der Wall E: The role of
hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J
Clin Pathol. 57:1009–1014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Carmeliet P, Dor Y, Herbert JM, et al:
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell
proliferation and tumour angiogenesis. Nature. 394:485–490. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Moritz W, Meier F, Stroka DM, et al:
Apoptosis in hypoxic human pancreatic islets correlates with
HIF-1alpha expression. FASEB J. 16:745–747. 2002.PubMed/NCBI
|
|
48.
|
Zhu P, Ning Y, Yao L, Chen M and Xu C: The
proliferation, apoptosis, invasion of endothelial-like epithelial
ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res.
29:1242010. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Sangwan V, Paliouras GN, Cheng A, Dube N,
Tremblay ML and Park M: Protein-tyrosine phosphatase 1B deficiency
protects against Fas-induced hepatic failure. J Biol Chem.
281:221–228. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Gonzalez-Rodriguez A, Escribano O, Alba J,
Rondinone CM, Benito M and Valverde AM: Levels of protein tyrosine
phosphatase 1B determine susceptibility to apoptosis in
serum-deprived hepatocytes. J Cell Physiol. 212:76–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Gu F, Nguyen DT, Stuible M, Dube N,
Tremblay ML and Chevet E: Protein-tyrosine phosphatase 1B
potentiates IRE1 signaling during endoplasmic reticulum stress. J
Biol Chem. 279:49689–49693. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Akasaki Y, Liu G, Matundan HH, et al: A
peroxisome proliferator-activated receptor-gamma agonist,
troglitazone, facilitates caspase-8 and -9 activities by increasing
the enzymatic activity of protein-tyrosine phosphatase-1B on human
glioma cells. J Biol Chem. 281:6165–6174. 2006. View Article : Google Scholar
|
|
53.
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Dahiya N and Morin PJ: MicroRNAs in
ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Shih KK, Qin LX, Tanner EJ, et al: A
microRNA survival signature (MiSS) for advanced ovarian cancer.
Gynecol Oncol. 121:444–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Giannakakis A, Sandaltzopoulos R, Greshock
J, et al: miR-210 links hypoxia with cell cycle regulation and is
deleted in human epithelial ovarian cancer. Cancer Biol Ther.
7:255–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Tsuchiya S, Fujiwara T, Sato F, et al:
MicroRNA-210 regulates cancer cell proliferation through targeting
fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem.
286:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Li T, Cao H, Zhuang J, et al:
Identification of miR-130a, miR-27b and miR-210 as serum biomarkers
for atherosclerosis obliterans. Clin Chim Acta. 412:66–70. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Puissegur MP, Mazure NM, Bertero T, et al:
miR-210 is overexpressed in late stages of lung cancer and mediates
mitochondrial alterations associated with modulation of HIF-1
activity. Cell Death Differ. 18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Ramon LA, Braza-Boils A, Gilabert J, et
al: microRNAs related to angiogenesis are dysregulated in
endometrioid endometrial cancer. Hum Reprod. 27:3036–3045. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Chen WY, Liu WJ, Zhao YP, et al:
Induction, modulation and potential targets of miR-210 in
pancreatic cancer cells. Hepatobiliary Pancreat Dis Int.
11:319–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Favaro E, Ramachandran A, McCormick R, et
al: MicroRNA-210 regulates mitochondrial free radical response to
hypoxia and krebs cycle in cancer cells by targeting iron sulfur
cluster protein ISCU. PLoS One. 5:e103452010. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Nakada C, Tsukamoto Y, Matsuura K, et al:
Overexpression of miR-210, a downstream target of HIF1alpha, causes
centrosome amplification in renal carcinoma cells. J Pathol.
224:280–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Noman MZ, Buart S, Romero P, et al:
Hypoxia-inducible miR-210 regulates the susceptibility of tumor
cells to lysis by cytotoxic T cells. Cancer Res. 72:4629–4641.
2012. View Article : Google Scholar : PubMed/NCBI
|
